Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Metoclopramide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR4 known ✓ | Q13639 | 5/20 | 0.93 |
| ▸ | HTR3A known ✓ | P46098 | 2/20 | 0.93 |
| ▸ | DRD2 known ✓ | P14416 | 2/20 | 0.93 |
| ▸ | CYP2D6 | P10635 | 4/20 | 0.93 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.93 |
| ▸ | ADRA2A | P08913 | 3/20 | 0.93 |
| ▸ | DRD3 | P35462 | 3/20 | 0.93 |
| ▸ | LMNA | P02545 | 3/20 | 0.93 |
| ▸ | HTR2B | P41595 | 2/20 | 0.93 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.93 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.93 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.93 |
| ▸ | HTR3B | O95264 | 1/20 | 0.93 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.93 |
| ▸ | MPO | P05164 | 1/20 | 0.93 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.93 |
| ▸ | DRD4 | P21917 | 1/20 | 0.93 |
| ▸ | HTR2A | P28223 | 1/20 | 0.93 |
| ▸ | HTR2C | P28335 | 1/20 | 0.93 |
| ▸ | HTR3D | Q70Z44 | 1/20 | 0.93 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Metoclopramide SCHEMBL678373 | 0.99 | HTR4 (0.95) | HTR4CYP2D6CYP1A2ADRA2ADRD3 | |
| Metoclopramide SCHEMBL678957 | 0.99 | HTR4 (0.95) | HTR4CYP2D6CYP1A2ADRA2ADRD3 | |
| Metoclopramide SCHEMBL8160010 | 0.98 | HTR4 (0.98) | HTR4CYP2D6CYP1A2ADRA2ADRD3 | |
| Metoclopramide SCHEMBL6569231 | 0.97 | RAB9A (0.98) | HTR4CYP2D6CYP1A2ADRA2ADRD3 | |
| Metoclopramide SCHEMBL18614363 | 0.97 | RAB9A (0.98) | HTR4CYP2D6CYP1A2ADRA2ADRD3 | |
| Metoclopramide SCHEMBL6263013 | 0.97 | RAB9A (0.98) | HTR4CYP2D6CYP1A2ADRA2ADRD3 | |
| Metoclopramide SCHEMBL133509 | 0.97 | RAB9A (0.98) | HTR4CYP2D6CYP1A2ADRA2ADRD3 | |
| Metoclopramide SCHEMBL5012583 | 0.97 | RAB9A (0.98) | HTR4CYP2D6CYP1A2ADRA2ADRD3 | |
| Metoclopramide SCHEMBL18629 | 0.96 | HTR4 (1.00) | HTR4CYP2D6CYP1A2ADRA2ADRD3 | |
| Metoclopramide SCHEMBL28222039 | 0.96 | HTR4 (1.00) | HTR4CYP2D6CYP1A2ADRA2ADRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 85 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11813304-B2 | Compounds and methods for inhibiting phosphate transport | ARDELYX, INC. (US) | 2023-11-14 | — | — | US | disclosed |
| US-20230277523-A1 | METHODS FOR INHIBITING PHOSPHATE TRANSPORT | ARDELYX, INC. (US) | 2023-09-07 | — | — | US | disclosed |
| EP-3884935-B1 | COMPOUNDS AND METHODS FOR INHIBITING PHOSPHATE TRANSPORT | ARDELYX INC (US) | 2023-06-14 | — | — | EP | disclosed |
| CN-114404588-A | Compounds and methods for inhibiting phosphate transport | 阿德利克斯公司 | 2022-04-29 | — | — | CN | disclosed |
| CN-114340631-A | Combination for reducing serum phosphate in a patient | 阿德利克斯股份有限公司 | 2022-04-12 | — | — | CN | disclosed |
| CN-105979959-B | Compounds and methods for inhibiting phosphate transport | 阿德利克斯公司 | 2021-11-30 | — | — | CN | disclosed |
| EP-3884935-A1 | COMPOUNDS AND METHODS FOR INHIBITING PHOSPHATE TRANSPORT | Ardelyx, Inc. (US) | 2021-09-29 | — | — | EP | disclosed |
| WO-2020237096-A1 | COMBINATION FOR LOWERING SERUM PHOSPHATE IN A PATIENT | ARDELYX, INC. (US) | 2020-11-26 | — | — | WO | disclosed |
| US-20200368223-A1 | METHODS FOR INHIBITING PHOSPHATE TRANSPORT | ARDELYX, INC. (US) | 2020-11-26 | — | — | US | disclosed |
| US-20200038475-A1 | COMPOUNDS AND METHODS FOR INHIBITING PHOSPHATE TRANSPORT | ARDELYX, INC. (US) | 2020-02-06 | — | — | US | disclosed |
| WO-2007104035-A1 | MODULATION OF NEUROGENESIS BY NOOTROPIC AGENTS | BRAINCELLS, INC. (US) | 2007-09-13 | — | — | WO | disclosed |
| US-20070208029-A1 | MODULATION OF NEUROGENESIS BY PDE INHIBITION | BRAINCELLS, INC. (US) | 2007-09-06 | — | — | US | disclosed |
| US-20070112017-A1 | GABA RECEPTOR MEDIATED MODULATION OF NEUROGENESIS | BRAINCELLS, INC. (US) | 2007-05-17 | — | — | US | disclosed |
| WO-2007053596-A1 | GABA RECEPTOR MEDIATED MODULATION OF NEUROGENESIS | BRAINCELLS, INC. (US) | 2007-05-10 | — | — | WO | disclosed |
| WO-2007047978-A2 | MODULATION OF NEUROGENESIS BY PDE INHIBITION | BRAINCELLS, INC. (US) | 2007-04-26 | — | — | WO | disclosed |
| US-20070078083-A1 | MODULATION OF NEUORGENESIS BY HDac INHIBITION | BRAINCELLS, INC. (US) | 2007-04-05 | — | — | US | disclosed |
| WO-2007030697-A2 | MODULATION OF NEUROGENESIS BY HDAC INHIBITION | BRAINCELLS, INC. (US) | 2007-03-15 | — | — | WO | disclosed |
| WO-2007025177-A2 | NEUROGENESIS BY MUSCARINIC RECEPTOR MODULATION | BRAINCELLS, INC. (US) | 2007-03-01 | — | — | WO | disclosed |
| US-20070049576-A1 | NEUROGENESIS BY MUSCARINIC RECEPTOR MODULATION | BRAINCELLS, INC. (US) | 2007-03-01 | — | — | US | disclosed |
| US-20070010543-A1 | Compositions and methods for treating gastrointestinal hypomotility and associated disorders | DYNOGEN PHARMACEUTICALS, INC. (US) | 2007-01-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070112017-A1 | GABA RECEPTOR MEDIATED MODULATION OF NEUROGENESIS | GABRB2, GAP43, GABRB1 | HTR4 672/4885HTR3A 574/4885DRD2 1115/4885 |
| US-20200368223-A1 | METHODS FOR INHIBITING PHOSPHATE TRANSPORT | SLC34A3, SLC34A2, SLC34A1 | HTR4 3153/4885HTR3A 1919/4885DRD2 4876/4885 |
| US-20070078083-A1 | MODULATION OF NEUORGENESIS BY HDac INHIBITION | DCX, BDNF, NTRK2 | HTR4 3498/4885HTR3A 3141/4885DRD2 4305/4885 |
| US-20070208029-A1 | MODULATION OF NEUROGENESIS BY PDE INHIBITION | PDE2A, PDE4A, DCX | HTR4 1626/4885HTR3A 1245/4885DRD2 2243/4885 |
| US-11813304-B2 | Compounds and methods for inhibiting phosphate transport | SLC34A3, SLC34A2, SLC34A1 | HTR4 1928/4885HTR3A 991/4885DRD2 4720/4885 |
| US-20230277523-A1 | METHODS FOR INHIBITING PHOSPHATE TRANSPORT | SLC34A3, SLC34A2, SLC34A1 | HTR4 3153/4885HTR3A 1919/4885DRD2 4876/4885 |
| US-20070049576-A1 | NEUROGENESIS BY MUSCARINIC RECEPTOR MODULATION | CHRNB2, CHAT, CHRNB4 | HTR4 521/4885HTR3A 353/4885DRD2 1528/4885 |
| US-20070010543-A1 | Compositions and methods for treating gastrointestinal hypomotility and associated disorders | HTR3A, HNMT, HTR3B | HTR4 4/4885HTR3A 1/4885DRD2 279/4885 |
| US-20200038475-A1 | COMPOUNDS AND METHODS FOR INHIBITING PHOSPHATE TRANSPORT | SLC34A3, SLC34A2, SLC34A1 | HTR4 1928/4885HTR3A 991/4885DRD2 4720/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.